Diadema Partners LP Uro Gen Pharma Ltd. Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Diadema Partners LP holds 150,000 shares of URGN stock, worth $3.62 Million. This represents 0.63% of its overall portfolio holdings.
Number of Shares
150,000
Previous 76,220
96.8%
Holding current value
$3.62 Million
Previous $843 Million
143.77%
% of portfolio
0.63%
Previous 0.22%
Shares
3 transactions
Others Institutions Holding URGN
# of Institutions
168Shares Held
39.6MCall Options Held
2.03MPut Options Held
717K-
Rtw Investments, LP New York, NY4.54MShares$110 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$77 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.48MShares$59.8 Million0.0% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$53.1 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$53 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $549M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...